Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides

Aeglea BioTherapeutics · 2023-05
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

38
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
show_traction
Open slide detailBeat · Traction
04
The slide uses a Gantt-style chart to represent clinical trial progress.plan_implementation
Open slide detailBeat · Traction
05
front_matter
Open slide detailBeat · Traction
06
frame_problem
Open slide detailBeat · Problem
07
Includes testimonials from KOLs to emphasize the difficulty of patient compliance.frame_problem
Open slide detailBeat · Problem
08
The slide uses a pie chart to segment patients and a timeline/number line to show age of diagnosis, followed by key metrics on clinical complications.frame_problem
Open slide detailBeat · Problem
09
Includes a biological process diagram showing intracellular vs plasma metabolism.present_solution
Open slide detailBeat · Solution
10
The slide outlines a multi-part clinical trial design with specific dosing cohorts and eligibility requirements.plan_implementation
Open slide detailBeat · Solution Approach
11
The chart displays efficacy data for a drug candidate (pegtarviliase) across different dosage cohorts.show_traction
Open slide detailBeat · Solution Approach
12
show_traction
Open slide detailBeat · Traction
13
ADA stands for Anti-Drug Antibodies.summarize
Open slide detailBeat · Traction
14
front_matter
Open slide detailBeat · Traction
15
The slide uses a timeline-based progression of symptoms to illustrate the severity of the disease.frame_problem
Open slide detailBeat · Traction
16
The slide uses a two-column layout to contrast commercial/regulatory status with clinical trial outcomes.establish_context
Open slide detailBeat · Traction
17
Includes box plots for arginine levels and bar charts for patient normalization rates.show_traction
Open slide detailBeat · Traction
18
Clinical trial data presentation with statistical significance markers and MCID thresholds.show_traction
Open slide detailBeat · Traction
19
The slide uses a heatmap to display individual patient outcomes across four metrics (pArg, GMFM-E, 2MWT, GMFM-D).show_traction
Open slide detailBeat · Traction
20
The slide presents clinical trial safety data comparing Pegzilarginase to a placebo group.analyze_data
Open slide detailBeat · Traction
21
transition
Open slide detailBeat · Traction
22
plan_implementation
Open slide detailBeat · Traction
23
The slide presents a standard quarterly financial comparison (P&L summary) and balance sheet highlights.analyze_data
Open slide detailBeat · Traction
24
front_matter
Open slide detailBeat · Traction
25
The slide uses a biological pathway diagram to explain the mechanism of action of the drug candidate.present_solution
Open slide detailBeat · TractionLoop · Before After
26
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.frame_problem
Open slide detailBeat · TractionLoop · Cost Of Inaction
27
The slide includes experimental design details and statistical significance markers (p < 0.05).analyze_data
Open slide detailBeat · Traction
28
Includes survival curve (Kaplan-Meier) and pharmacodynamic response (tHcy levels over time).analyze_data
Open slide detailBeat · Traction
29
Includes histological images of liver tissue and a dot plot showing bone mineral density (BMD) improvement.show_traction
Open slide detailBeat · Traction
30
The table displays mean/SD, range, and counts/percentages for Pegzilarginase (n=21), Placebo (n=11), and Overall (N=32).analyze_data
Open slide detailBeat · Traction
31
Data includes Plasma Arginine, GMFCS level, GMFM-E, and 2MWT metrics.analyze_data
Open slide detailBeat · Traction
32
The chart is a box-and-whisker plot showing longitudinal data from baseline through 56 weeks.show_traction
Open slide detailBeat · Traction
33
Includes both continuous mean change data and categorical responder analysis.analyze_data
Open slide detailBeat · Traction
34
Includes a study design timeline at the bottom right and MCID reference lines on the GMFM-E chart.analyze_data
Open slide detailBeat · Traction
35
Slide details GMFCS classification levels and GMFM/Timed Walk Test methodologies.establish_context
Open slide detailBeat · Traction
36
The slide uses a process flow diagram to illustrate the clinical trial structure.plan_implementation
Open slide detailBeat · Traction
37
The slide highlights clinical response in specific patients, emphasizing normalization of mobility metrics.show_traction
Open slide detailBeat · Traction
38
The slide uses a split-screen layout: left side is market sizing/geographic distribution, right side is a 2x2 matrix of launch activities.plan_implementation
Open slide detailBeat · TractionLoop · Quick Win Big Bet